Article
Oncology
Eeeln Buckarma, Cornelius A. Thiels, Zhaohui Jin, Travis E. Grotz
Summary: CRS and HIPEC with paclitaxel and cisplatin is well tolerated and associated with favorable oncologic and perioperative outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Naminatsu Takahara, Yousuke Nakai, Hironori Ishigami, Kei Saito, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Tomotaka Saito, Tsuyoshi Hamada, Suguru Mizuno, Hirofumi Kogure, Hiroharu Yamashita, Hiroyuki Isayama, Yasuyuki Seto, Kazuhiko Koike
Summary: This study investigated the maximum tolerated dose and recommended dose of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel in pancreatic cancer patients with peritoneal metastasis. The results showed the feasibility and potential effectiveness of this treatment regimen as a first-line therapy for pancreatic cancer patients with peritoneal metastasis.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Oncology
So Hyun Kang, Sa-Hong Min, Jin Won Kim, Eunju Lee, Sang Woo Park, Sangjun Lee, Hyeon Jeong Oh, Young Suk Park, Yoon Jin Lee, Ji-Won Kim, Sang-Hoon Ahn, Yun-Suhk Suh, Keun-Wook Lee, Hye Seung Lee, Hyung-Ho Kim
Summary: This study aimed to determine the recommended phase II dose for gastric cancer patients through intraperitoneal paclitaxel combined with intravenous fluorouracil, leucovorin, and oxaliplatin. The results showed that this treatment regimen is safe, and the recommended phase II dose of IP paclitaxel is 60 mg/m(2).
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Zhong-Yin Yang, Fei Yuan, Sheng Lu, Wei Xu, Jun-Wei Wu, Wen-Qi Xi, Min Shi, Zhen-Qiang Wang, Zhen-Tian Ni, Chang-Yu He, Xue-Xin Yao, Ya-Nan Zheng, Zheng-Lun Zhu, Wen-Tao Liu, Jun Zhang, Huan Zhang, Chen Li, Chao Yan, Min Yan, Zheng-Gang Zhu
Summary: This study demonstrates that NIPS is effective and safe in treating gastric cancer patients with peritoneal metastasis in China. Male patients, patients who underwent R0 resection, and patients with ypN0-1 or TRG1 after conversion surgery are more likely to benefit from NIPS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Min Shi, Zhongyin Yang, Sheng Lu, Wentao Liu, Zhentian Ni, Xuexin Yao, Zichen Hua, Runhua Feng, Yanan Zheng, Zhenqiang Wang, Birendra Kumar Sah, Mingmin Chen, Zhenglun Zhu, Changyu He, Chen Li, Jun Zhang, Chao Yan, Min Yan, Zhenggang Zhu
Summary: The study evaluated the efficacy and safety of oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. The combination therapy showed promising results in improving survival rates with relatively low grade 3-4 toxicities. Large-scale clinical trials are needed for further confirmation of its efficacy.
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Surgery
Masayuki Shinkai, Motohiro Imano, Yoko Hiraki, Kota Momose, Hiroaki Kato, Osamu Shiraishi, Atsushi Yasuda, Masanobu Tsubaki, Shozo Nishida, Takushi Yasuda
Summary: Conversion surgery is safe and may prolong survival for gastric cancer patients with peritoneal metastasis who have responded to single i.p. PTX plus systemic chemotherapy.
LANGENBECKS ARCHIVES OF SURGERY
(2022)
Article
Oncology
Jianping Guo, Zijian Deng, Longyang Jin, Shi Yin, Zhizhong Xiong, Caiqin Wang, Huaxian Chen, Dandong Luo, Dayin Huang, Junsheng Peng, Shi Chen, Lei Lian
Summary: This study aims to investigate the real-world application and efficacy of HIPEC alone for GC patients with synchronous peritoneal metastases. The results show that HIPEC can only improve the survival rate of gastric cancer patients when combined with primary tumor resection.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Daryl K. A. Chia, Raghav Sundar, Guowei Kim, Jia Jun Ang, Jeffrey H. Y. Lum, Min En Nga, Giap Hean Goh, Ju Ee Seet, Cheng Ean Chee, Hon Lyn Tan, Jingshan Ho, Natalie Y. L. Ngoi, Matilda X. W. Lee, Vaishnavi Muthu, Gloria H. J. Chan, Angela S. L. Pang, Yvonne L. E. Ang, Joan R. E. Choo, Joline S. J. Lim, Jun Liang Teh, Aung Lwin, Yuen Soon, Asim Shabbir, Jimmy B. Y. So, Wei Peng Yong
Summary: This study aimed to evaluate the use of IP-PTX with XELOX for GCPM. Compared with the SC group, the IP group achieved better results in overall survival and progression-free survival. In the IP group, patients who underwent conversion surgery had a median overall survival of 24.2 months and a 1-year overall survival rate of 84.6%.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Immunology
Kazuya Takahashi, Kentaro Kurashina, Hironori Yamaguchi, Rihito Kanamaru, Hideyuki Ohzawa, Hideyo Miyato, Shin Saito, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
Summary: Patients with peritoneal metastases show decreased proportions of CD8(+) T cells, NKT-like cells, and NK cells, along with increased proportions of B cells and macrophages with enhanced expression of specific markers. These alterations in the immune cell phenotypes in the peritoneal cavity might play a role in the development and progression of intraperitoneal tumor growth.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Wim Ceelen, Louis Sandra, Leen Van de Sande, Martin Graversen, Michael Bau Mortensen, An Vermeulen, Elke Gasthuys, Dries Reynders, Sarah Cosyns, Anne Hoorens, Wouter Willaert
Summary: In this Phase I study, the tolerability, safety, pharmacokinetics, and tumour response of nanoparticle albumin bound paclitaxel (NAB-PTX) during pressurized intraperitoneal aerosolized chemotherapy (PIPAC) were investigated. The results showed a favorable pharmacokinetic profile and promising anticancer activity of PIPAC with NAB-PTX in patients with unresectable peritoneal metastases.
Article
Oncology
Taiki Nakashima, Takaaki Arigami, Yoshikazu Uenosono, Daisuke Matsushita, Masataka Shimonosono, Yusuke Tsuruda, Ken Sasaki, Kenji Baba, Hiroshi Kurahara, Takao Ohtsuka
Summary: Intraperitoneal paclitaxel chemotherapy improves tumor response and increases the success rate of conversion surgery in patients with peritoneal metastasis of gastric cancer. However, it does not affect the overall prognosis. It can be considered as an important option for personalized treatment.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jiaxin Luo, Lingxi Jiang, Changyu He, Minmin Shi, Zhong-Yin Yang, Min Shi, Sheng Lu, Chen Li, Jun Zhang, Min Yan, Zheng-Gang Zhu, Chao Yan
Summary: This study found that the expression levels of microRNAs in peritoneal lavage samples of gastric cancer patients are associated with peritoneal metastasis. Specifically, hsa-let-7g-3p and hsa-miR-10395-3p have been identified as biomarkers predicting peritoneal metastasis and the efficacy of intraperitoneal chemotherapy.
Review
Oncology
Aruna Prabhu, Deepti Mishra, Andreas Brandl, Yutaka Yonemura
Summary: The treatment of peritoneal metastasis from gastric cancer is evolving, with intraperitoneal chemotherapy showing promising results. Individualized treatment options can be chosen based on patients' condition, but further validation is needed outside of Asia where most trials have been conducted.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Li Tu, Weihan Zhang, Lu Ni, Zihan Xu, Kun Yang, Hongfeng Gou, Qing Zhu, Ming Liu, Yu Yang, Jiankun Hu, Meng Qiu
Summary: This study evaluated the efficacy and safety of intraperitoneal high-dose paclitaxel combined with systemic SOX as a first-line treatment for patients with peritoneal metastatic gastric cancer. The results demonstrated that this regimen is effective and well-tolerated in this patient population.
Article
Oncology
Tomoharu Miyashita, Hidehiro Tajima, Isamu Makino, Mitsuyoshi Okazaki, Takahisa Yamaguchi, Yoshinao Ohbatake, Sinichi Nakanuma, Hironori Hayashi, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Koji Kishimoto, John W. Harmon, Tetsuo Ohta
ANTICANCER RESEARCH
(2018)
Article
Surgery
Hironori Hayashi, Hiroyuki Takamura, Yoshinao Ohbatake, Shinichi Nakanuma, Hidehiro Tajima, Sachio Fushida, Ichiro Onishi, Takashi Tani, Koichi Shimizu, Tetsuo Ohta
ASIAN JOURNAL OF SURGERY
(2018)
Article
Gastroenterology & Hepatology
Takashi Miyata, Hidehiro Tajima, Miki Hirata, Shin-ichi Nakanuma, Isamu Makino, Hironori Hayashi, Katsunobu Oyama, Tomoharu Miyashita, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Shoichi Iseki, Shin-ichi Harada, Tomohiko Wakayama, Tetsuo Ohta
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2018)
Article
Surgery
Tomoharu Miyashita, Toru Kono, Daisuke Matsui, Yuki Yamazaki, Daichi Sadatomi, Naoki Fujitsuka, Shinichi Nakanuma, Koichi Okamoto, Isamu Makino, Jun Kinoshita, Keishi Nakamura, Katsunobu Oyama, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Kenichi Mukaisho, John W. Harmon, Tetsuo Ohta
Article
Gastroenterology & Hepatology
Koichi Okamoto, Itasu Ninomiya, Takahisa Yamaguchi, Shiro Terai, Shinichi Nakanuma, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Sachio Fushida, Tetsuo Ohta
Article
Surgery
Hironori Hayashi, Hidehiro Tajima, Kazuhiro Hanazaki, Hiroyuki Takamura, Ryosuke Gabata, Mitsuyoshi Okazaki, Yoshinao Ohbatake, Shinichi Nakanuma, Isamu Makino, Tomoharu Miyashita, Itasu Ninomiya, Sachio Fushida, Kenichi Yoshimura, Tetsuo Ohta
ASIAN JOURNAL OF SURGERY
(2020)
Editorial Material
Gastroenterology & Hepatology
Koichi Okamoto, Itasu Ninomiya, Yuta Fujiwara, Ichitaro Mochizuki, Tatsuya Aoki, Takahisa Yamaguchi, Shiro Terai, Shinichi Nakanuma, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Sachio Fushida, Tetsuo Ohta
Article
Oncology
Tomoharu Miyashita, Hidehiro Tajima, Ryosuke Gabata, Mitsuyoshi Okazaki, Hiroyuki Shimbashi, Yoshinao Ohbatake, Koichi Okamoto, Sinichi Nakanuma, Seisho Sakai, Isamu Makino, Jun Kinoshita, Hironori Hayashi, Keishi Nakamura, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, John W. Harmon, Tetsuo Ohta
ANTICANCER RESEARCH
(2019)
Article
Surgery
Mitsuyoshi Okazaki, Hidehiro Tajima, Yoshinao Ohbatake, Hiroyuki Shinbashi, Shinichi Nakanuma, Isamu Makino, Itasu Ninomiya, Sachio Fushida, Koushiro Ohtsubo, Tetsuo Ohta
Article
Gastroenterology & Hepatology
Tomokazu Tokoro, Isamu Makino, Shinichi Harada, Koichi Okamoto, Shinichi Nakanuma, Seisho Sakai, Jun Kinoshita, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
Article
Oncology
Takahisa Yamaguchi, Sachio Fushida, Jun Kinoshita, Mitsuyoshi Okazaki, Satoko Ishikawa, Yoshinao Ohbatake, Shiro Terai, Koichi Okamoto, Shinichi Nakanuma, Isamu Makino, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Tetsuo Ohta
Article
Surgery
Shinichi Nakanuma, Hidehiro Tajima, Hiroyuki Takamura, Seisho Sakai, Ryosuke Gabata, Mitsuyoshi Okazaki, Hiroyuki Shinbashi, Yoshinao Ohbatake, Isamu Makino, Hironori Hayashi, Tomoharu Miyashita, Sachio Fushida, Tetsuo Ohta
ANNALS OF TRANSPLANTATION
(2020)
Article
Medicine, Research & Experimental
Shunsuke Kanou, Tomoharu Miyashita, Yasuhiko Yamamoto, Satoshi Takada, Makoto Nakura, Mitsuyoshi Okazaki, Yoshinao Ohbatake, Shinichi Nakanuma, Isamu Makino, Hidehiro Tajima, Hiroyuki Takamura, Sachio Fushida, Tetsuo Ohta
Article
Oncology
Hidehiro Tajima, Tetsuo Ohta, Mitsuyoshi Okazaki, Takahisa Yamaguchi, Yoshinao Ohbatake, Koichi Okamoto, Shinichi Nakanuma, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Tomoharu Miyashita, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Hiroyuki Nakamura
MOLECULAR AND CLINICAL ONCOLOGY
(2019)
Article
Medicine, Research & Experimental
Satoshi Takada, Tomoharu Miyashita, Yasuhiko Yamamoto, Shunsuke Kanou, Seiichi Munesue, Yoshinao Ohbatake, Shinichi Nakanuma, Koichi Okamoto, Seisho Sakai, Jun Kinoshita, Isamu Makino, Keishi Nakamura, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta